Thu, March 3, 2011
Wed, March 2, 2011
[ Wed, Mar 02nd 2011 ] - Market Wire
BURCON AMENDS LETTER OF INTENT
Tue, March 1, 2011
Mon, February 28, 2011
Sun, February 27, 2011
Fri, February 25, 2011
Thu, February 24, 2011
Wed, February 23, 2011
Tue, February 22, 2011
[ Tue, Feb 22nd 2011 ] - Market Wire
PROTOX APPOINTS NEW DIRECTORS
Mon, February 21, 2011
Sun, February 20, 2011
Fri, February 18, 2011
Thu, February 17, 2011
Wed, February 16, 2011
Tue, February 15, 2011

Somaxon Pharmaceuticals to Report Full Year and Fourth Quarter Ended December 31, 2010 Financial Results and Conduct Conference


//health-fitness.news-articles.net/content/2011/ .. 10-financial-results-and-conduct-conference.html
Published in Health and Fitness on Wednesday, February 23rd 2011 at 13:11 GMT by Market Wire   Print publication without navigation


SAN DIEGO--([ BUSINESS WIRE ])--Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX), a specialty pharmaceutical company, today announced that it will release its full year and fourth quarter ended December 31, 2010 financial results on Thursday, March 3, 2011 after the closing of the U.S. financial markets. Somaxon management will conduct a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to review these financial results and answer questions.

The conference call will be available to interested parties through a live audio Internet broadcast at [ http://investors.somaxon.com/eventdetail.cfm ]. The call will also be archived and accessible at this site for approximately two weeks. Alternatively, callers may participate in the conference call by dialing (877) 941-8609 (domestic) or (480) 629-9820 (international), conference call ID 4415379. A telephonic replay will be available for approximately two weeks following the conclusion of the call by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international), and entering passcode 4415379.

To be added to Somaxon Pharmaceuticalsa™ email list, please visit [ http://bit.ly/Somaxon-email-list ].

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and of late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxona™s product Silenor®, now available by prescription in the United States, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

For more information, please visit the companya™s web site at [ www.somaxon.com ].


Publication Contributing Sources